{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:17Z","timestamp":1793939417607,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106669","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T16:00:54Z","timestamp":1755100854000},"page":"106669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A comparative study on clinico-radiological profile, treatment responses and outcomes of double seronegative NMOSD compared to AQP4-IgG positive NMOSD, and MOGAD"],"prefix":"10.1016","volume":"103","author":[{"given":"Radhika Sanjay","family":"Lotlikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi S.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Narasimhaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bejoy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-0878","authenticated-orcid":false,"given":"Soumya","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106669_bib0001","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1590\/0004-282X20130021","article-title":"Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica","volume":"71","author":"Abaroa","year":"2013","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106669_bib0002","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies","volume":"11","author":"Asseyer","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106669_bib0003","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106669_bib0004","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Bilodeau","year":"2024","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2025.106669_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30633","article-title":"The distinction of area postrema syndrome between MOGAD and NMOSD","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon."},{"key":"10.1016\/j.msard.2025.106669_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12883-016-0721-1","article-title":"The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica","volume":"16","author":"Cheng","year":"2016","journal-title":"BMC. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106669_bib0007","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMa Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106669_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106669_bib0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2025.106669_bib0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0011","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics."},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200183","article-title":"Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria","volume":"11","author":"Forcadela","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.msard.2025.106669_bib0014","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106669_bib0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106669_bib0016","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fneur.2020.00396","article-title":"Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies","volume":"11","author":"Hyun","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106669_bib0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation."},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0018","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation."},{"issue":"7","key":"10.1016\/j.msard.2025.106669_bib0020","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106669_bib0021","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.msard.2025.106669_bib0022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106669_bib0023","doi-asserted-by":"crossref","first-page":"E2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106669_bib0024","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"9451","key":"10.1016\/j.msard.2025.106669_bib0026","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106669_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106669_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.msard.2025.106669_bib0029","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106669_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577742","article-title":"Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature","volume":"361","author":"Nagireddy","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106669_bib0031","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106669_bib0032","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4103\/0028-3886.294831","article-title":"Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated CNS Demyelination: Clinical Spectrum and Comparison with Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder","volume":"68","author":"Ojha","year":"2020","journal-title":"Neurol. India"},{"key":"10.1016\/j.msard.2025.106669_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00960","article-title":"The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults","volume":"11","author":"Parrotta","year":"2020","journal-title":"Front Neurol;"},{"issue":"7","key":"10.1016\/j.msard.2025.106669_bib0034","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106669_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106669_bib0036","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10072-022-06409-w","article-title":"Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina","volume":"44","author":"Rojas","year":"2023","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.msard.2025.106669_bib0037","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1016\/j.msard.2025.106669_bib0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.25259\/JNRP_32_2022","article-title":"A comparative analysis of demographic, clinical and imaging features of myelin oligodendrocyte glycoprotein antibody positive, aquaporin 4 antibody positive, and double seronegative demyelinating disorders - An Indian tertiary care center prospective study","volume":"14","author":"Salunkhe","year":"2023","journal-title":"J. Neurosci. Rural. Pract."},{"key":"10.1016\/j.msard.2025.106669_bib0039","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.msard.2025.106669_bib0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.msard.2025.106669_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.msard.2025.106669_bib0042","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106669_bib0043","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"11-12","key":"10.1016\/j.msard.2025.106669_bib0044","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106669_bib0045","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1212\/NXI.0000000000000626","article-title":"Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling","volume":"6","author":"Yeo","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:20:12Z","timestamp":1774999212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"alternative-id":["S2211034825004110"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106669","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative study on clinico-radiological profile, treatment responses and outcomes of double seronegative NMOSD compared to AQP4-IgG positive NMOSD, and MOGAD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106669"}}